Search research articles
Contact Us
Filters
Showing results (1-10 of 53) with videos related to
Page
of 6
Sort By:
Clinical Pharmacology and Therapeutics
|
June 27, 2026
Reply to: "The Future of Clinical Pharmacology: The Right Medicine at the Right Dose for Each Patient"
Matthew L Rizk, Sandra A G Visser
Clinical Pharmacology and Therapeutics
|
December 23, 2025
The Role for Clinical Translational Pharmacology in Advancing Pharmacoequity
Sonya Tang Girdwood, Sandra A G Visser
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
August 17, 2017
Assessment of translational risk in drug research: Role of biomarker classification and mechanism-based PKPD concepts
Sandra A G Visser, Tjerk J H Bueters
Future Medicinal Chemistry
|
November 25, 2015
Optimization of human dose prediction by using quantitative and translational pharmacology in drug discovery
Tjerk Bueters, Christopher Gibson, Sandra A G Visser
Drug Discovery Today
|
May 14, 2013
The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives
Tjerk Bueters, Bart A Ploeger, Sandra A G Visser
Clinical Pharmacology and Therapeutics
|
April 8, 2025
ASCPT 125th Anniversary: A Society Leadership Perspective
Matthew L Rizk, Abigail Gorman, Sandra A G Visser
Clinical and Translational Science
|
July 17, 2024
How debunking biases in research and development decisions could lead to more equitable healthcare?
Benjamin Weber, Issam Zineh, Richard Lalonde, et al.
Drug Discovery Today
|
October 9, 2008
Correct assessment of new compounds using in vivo screening models can reduce false positives
Tjerk J H Bueters, Janet Hoogstraate, Sandra A G Visser
The Journal of Biological Chemistry
|
November 16, 2012
Interplay between α-, β-, and γ-secretases determines biphasic amyloid-β protein level in the presence of a γ-secretase inhibitor
Fernando Ortega, Jonathan Stott, Sandra A G Visser, et al.
Clinical Pharmacology and Therapeutics
|
February 25, 2025
The Unrealized Potential of Advanced Modeling Methods to Inform Early Strategic Planning for Payer Reimbursement
Ananth Kadambi, Nicholas C Anderson, Sandra A G Visser, et al.
Page
of 6
Search research articles
Search
Showing results (1-10 of 53) with videos related to
Sort By:
Page
of 6
Clinical Pharmacology and Therapeutics
|
June 27, 2026
Reply to: "The Future of Clinical Pharmacology: The Right Medicine at the Right Dose for Each Patient"
Matthew L Rizk, Sandra A G Visser
Clinical Pharmacology and Therapeutics
|
December 23, 2025
The Role for Clinical Translational Pharmacology in Advancing Pharmacoequity
Sonya Tang Girdwood, Sandra A G Visser
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
August 17, 2017
Assessment of translational risk in drug research: Role of biomarker classification and mechanism-based PKPD concepts
Sandra A G Visser, Tjerk J H Bueters
Future Medicinal Chemistry
|
November 25, 2015
Optimization of human dose prediction by using quantitative and translational pharmacology in drug discovery
Tjerk Bueters, Christopher Gibson, Sandra A G Visser
Drug Discovery Today
|
May 14, 2013
The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives
Tjerk Bueters, Bart A Ploeger, Sandra A G Visser
Clinical Pharmacology and Therapeutics
|
April 8, 2025
ASCPT 125th Anniversary: A Society Leadership Perspective
Matthew L Rizk, Abigail Gorman, Sandra A G Visser
Clinical and Translational Science
|
July 17, 2024
How debunking biases in research and development decisions could lead to more equitable healthcare?
Benjamin Weber, Issam Zineh, Richard Lalonde, et al.
Drug Discovery Today
|
October 9, 2008
Correct assessment of new compounds using in vivo screening models can reduce false positives
Tjerk J H Bueters, Janet Hoogstraate, Sandra A G Visser
The Journal of Biological Chemistry
|
November 16, 2012
Interplay between α-, β-, and γ-secretases determines biphasic amyloid-β protein level in the presence of a γ-secretase inhibitor
Fernando Ortega, Jonathan Stott, Sandra A G Visser, et al.
Clinical Pharmacology and Therapeutics
|
February 25, 2025
The Unrealized Potential of Advanced Modeling Methods to Inform Early Strategic Planning for Payer Reimbursement
Ananth Kadambi, Nicholas C Anderson, Sandra A G Visser, et al.
Page
of 6